Fujifilm is leveraging its strengths in advanced production, analysis and engineering technologies cultivated through the development and manufacture of a wide range of products, including photographic film, for its biopharmaceutical contract development and manufacturing business (Bio CDMO business) and its Life Sciences business which provides drug discovery support materials such as iPS cells and cell culture media.
Biopharmaceuticals have emerged as a promising solution including intractable and rare diseases. The market is expected to grow at a compound annual growth rate of 9% from 2023 to 2030*1 . On the other hand, the manufacturing of biopharmaceuticals requires advanced production technologies and equipment, leading to an increase in cases where pharmaceutical companies outsource process development and manufacturing to CDMOs*2.
The Fujifilm Group possesses industry-leading cultivation and production technologies, and offers contract manufacturing services for biopharmaceuticals, including one-stop solutions for process development, manufacturing of drug substances, formulation, and packaging.
- *1 Our focus market, excluding Vaccines, etc. Fujifilm estimation based on EvaluatePharma (Download: 2025 Jan 9)
- *2 Abbreviation for Contract Development & Manufacturing Organization. Providing pharmaceutical companies with various services such as cell line development in early development stage, production process development, stability testing, development and manufacturing of investigational drugs and manufacturing of commercial drugs.
In our Life Sciences business, we support pharmaceutical companies engaged in the research, development, and manufacturing of biopharmaceuticals by providing essential products such as “cells,” primarily iPS cells, “cell culture media” containing nutrients for cell growth and proliferation, and “reagents” for performance and quality verification. Additionally, our group company, FUJIFILM Cellular Dynamics, Inc., is involved in contract development and manufacturing of cellular therapies utilizing iPS cells.